Guided Therapeutics' LuViva® Advanced Cervical Scan Cited as Promising Solution to Reduce Unnecessar
Guided Therapeutics' LuViva ® Advanced Cervical Scan Cited as Promising Solution to Reduce Unnecessary, Painful and Costly Procedures in European Healthcare Settings
Official reference book of European Hospital and Healthcare Federation article highlights LuViva
LONDON--(BUSINESS WIRE)-- Up to 40 percent of women currently undergoing unnecessary procedures for cervical disease diagnosis could avoid the psychological and financial burdens and the potential for medical complications from treatment if given a non-invasive test with the LuViva® Advanced Cervical Scan, according to an article appearing in the Hospital Healthcare Europe 2013 Bulletin journal (page 115). According to the article, in addition to an emotional impact, women undergoing additional testing after a suspicious Pap test reported physical effects of the unnecessary testing that included moderate to severe pain, moderate to severe bleeding and changes in their first menstrual period post colposcopy and biopsy.
"Including LuViva into the current cervical screening models after, or in conjunction with, initial screening tests, but before colposcopy, would not only give physicians more confidence in determining if actual disease is present, but also would eliminate unnecessary follow up tests, biopsies and other procedures on healthy patients by 35 to 40 percent," wrote the article's author Leo B. Twiggs, MD, Professor of Obstetrics and Gynecology at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. "This will significantly reduce the emotional and physical trauma to the patient and, by returning the patient to their normal screening intervals sooner, would also reduce the financial burden for both the patient and the payer."
"This article highlights the powerful potential that LuViva has to positively change the way healthcare systems and patients view cervical disease detection," said Mark L. Faupel, Ph.D., CEO and president of Guided Therapeutics, Inc. "Even though the guidelines for screening cervical cancer are evolving and differ from country to country, LuViva is viewed by many leading physicians as designed to address these changes, while bringing efficiencies and improvements to the patient's experience."
About HHE -
Hospital Healthcare Europe (HHE) is the official best practice reference title of HOPE - the European Hospital and Healthcare Federation. Provided to the hospital Chief Executive and Departmental Directors of some 17,000+ public and private sector hospitals in the UK and European Union, HHE is an indispensable resource for best practice information, pan-European guidelines and clinician-authored case-studies of today's leading medical centers in Europe.
HOPE, the European Hospital and Healthcare Federation, is an international non-profit organization, created in 1966. HOPE represents national public and private hospital associations and hospital owners, either federations of local and regional authorities or national health services. Today, HOPE is made up of 34 organizations coming from the 27 Member States of the European Union, Switzerland and the Republic of Serbia. HOPE's mission is to promote improvements in the health of citizens throughout Europe, high standard of hospital care and to foster efficiency with humanity in the organization and operation of hospital and healthcare services.
The LuViva Advanced Cervical Scan is compliant with both Edition 2 and Edition 3 CE standards, has marketing approval from Health Canada and the Singapore Health Sciences Authority, and is under U.S. Food and Drug Administration Premarket review.
About LuViva ® Advanced Cervical Scan
LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which eliminates costly, painful and unnecessary testing. LuViva is designed for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. The device is used in conjunction with the LuViva® Cervical Guide single-use patient interface and calibration disposable.
About Guided Therapeutics
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is developing a rapid and painless testing platform for the early detection of disease based on its patented biophotonic technology that utilizes light to detect disease at the cellular level. The Company's first planned product is the LuViva®Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. Guided Therapeutics is also developing a non-invasive test for the early detection of esophageal cancer using the technology platform. For more information, visit: www.guidedinc.com.
The Guided Therapeutics LuViva ® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.
Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics' actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading "Risk Factors" in Guided Therapeutics' reports filed with the SEC, including Guided Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2012.
Alison Ziegler, 212-554-5469
Bill Wells, 770-242-8723 Ext. 241
KEYWORDS: United Kingdom United States Europe North America Georgia
The article Guided Therapeutics' LuViva® Advanced Cervical Scan Cited as Promising Solution to Reduce Unnecessary, Painful and Costly Procedures in European Healthcare Settings originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.